Skip to main content

Table 1 Clinical characteristics of responders and non-responders at baseline

From: Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis

 RespondersNon-respondersp value
Number of patients278 
Age, year59.4 ± 13.167.4 ± 12.5N.S.
Female, n (%)22 (81.5)5 (62.5)N.S.
Disease duration, month109.2 ± 147.950.25 ± 56.7N.S.
RF titer, mg/dl69.7 ± 78.3(n = 26)83.5 ± 74.3N.S.
RF positivity, n (%)20 (76.9)8 (100)N.S.
Anti-CCP antibody titer, U/ml92.8 ± 94.0(n = 25)120.7 ± 117N.S.
Anti-CCP antibody positivity, n (%)25 (91.6)8 (100)N.S.
DAS28-CRP4.37 ± 1.043.81 ± 0.98N.S.
Use of PSL, n (%)5 (18.5)3 (37.5)N.S.
PSL dose, mg/day6.4 ± 5.010.25 ± 7.2N.S.
Use of MTX, n (%)19 (70.0)2 (25.0)0.04
MTX dose, mg/week10.61 ± 3.79.0 ± 4.2N.S.
  1. Values are expressed as the mean ± SD. Fisher’s exact test and Student’s t test were used to compare categorical and continuous variables between the two groups, respectively. p < 0.05 was considered statistically significant
  2. N.S. not significant, RF rheumatoid factor, CCP cyclic citrullinated peptide, DAS28-CRP disease activity score in 28 joints using C-reactive protein, PSL prednisolone, MTX methotrexate